Publication:
Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI.

Simple item page
dc.contributor.authorVallejo-Vaz, Antonio J
dc.contributor.authorBray, Sarah
dc.contributor.authorVilla, Guillermo
dc.contributor.authorBrandts, Julia
dc.contributor.authorKiru, Gaia
dc.contributor.authorMurphy, Jennifer
dc.contributor.authorBanach, Maciej
dc.contributor.authorDe Servi, Stefano
dc.contributor.authorGaita, Dan
dc.contributor.authorGouni-Berthold, Ioanna
dc.contributor.authorKees Hovingh, G
dc.contributor.authorJozwiak, Jacek J
dc.contributor.authorJukema, J Wouter
dc.contributor.authorGabor Kiss, Robert
dc.contributor.authorKownator, Serge
dc.contributor.authorIversen, Helle K
dc.contributor.authorMaher, Vincent
dc.contributor.authorMasana, Luis
dc.contributor.authorParkhomenko, Alexander
dc.contributor.authorPeeters, André
dc.contributor.authorClifford, Piers
dc.contributor.authorRaslova, Katarina
dc.contributor.authorSiostrzonek, Peter
dc.contributor.authorRomeo, Stefano
dc.contributor.authorTousoulis, Dimitrios
dc.contributor.authorVlachopoulos, Charalambos
dc.contributor.authorVrablik, Michal
dc.contributor.authorCatapano, Alberico L
dc.contributor.authorPoulter, Neil R
dc.contributor.authorRay, Kausik K
dc.contributor.authorDA VINCI Study Investigators
dc.date.accessioned2023-05-03T13:38:19Z
dc.date.available2023-05-03T13:38:19Z
dc.date.issued2022-05-14
dc.description.abstractLow-density lipoprotein cholesterol (LDL-C) recommendations differ between the 2018 American College of Cardiology/American Heart Association (ACC/AHA) and 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines for patients with atherosclerotic cardiovascular disease (ASCVD) ( DA VINCI was a cross-sectional observational study of patients prescribed lipid-lowering therapy (LLT) across 18 European countries. Ten-year cardiovascular risk (CVR) was predicted among ASCVD patients receiving stabilized LLT. For patients with LDL-C ≥ 70 mg/dl, the absolute LDL-C reduction required to achieve an LDL-C of  Of the 2039 patients, 61% did not achieve LDL-C  In ASCVD patients, achieving ESC/EAS LDL-C goals could result in a 2% additional ARR over 10 years versus the ACC/AHA approach.
dc.identifier.doi10.1007/s10557-022-07343-x
dc.identifier.essn1573-7241
dc.identifier.pmid35567726
dc.identifier.unpaywallURLhttps://link.springer.com/content/pdf/10.1007/s10557-022-07343-x.pdf
dc.identifier.urihttp://hdl.handle.net/10668/20496
dc.journal.titleCardiovascular drugs and therapy
dc.journal.titleabbreviationCardiovasc Drugs Ther
dc.language.isoen
dc.organizationHospital Universitario Virgen del Rocío
dc.organizationInstituto de Biomedicina de Sevilla-IBIS
dc.pubmedtypeJournal Article
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectAtherosclerotic cardiovascular disease
dc.subjectCardiovascular disease prevention
dc.subjectCardiovascular risk
dc.subjectLDL-C
dc.subjectLipid-lowering
dc.subjectStatins
dc.titleImplications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI.
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication

Files

Collections

SAS - Hospital Universitario Virgen del Rocío
Instituto de Investigación Biomédica de Sevilla (IBIS)

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía